PATH to use Liquidia particle technology for malaria

The PATH Malaria Vaccine Initiative (MVI) will have use of Liquidia Technologies' PRINT particle technology for its research into new, more effective malaria vaccines. The technology helps researchers control the size, shape and chemistry of protein particles used in the malaria vaccine.

"MVI is actively working to identify second generation vaccine approaches with the potential to elicit higher levels of efficacy over a longer period of time; approaches that could target the disease as well as parasite transmission, which will be important in the fight to control and eliminate malaria," said Ashley Birkett, director of Pre- and Early Clinical Research and Development at MVI, in a statement. "The PRINT technology represents an advancement in the controlled delivery of vaccine components, which may enhance efficacy and safety by bringing together multiple technologies necessary to achieve a next-generation malaria vaccine."

- see the Liquidia release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.